| 2026-08-13 | 10-Q | 10.3 | Offer Letter Agreement by and between the Registrant and Judith Matthews, dated as of June 3, 2026 |
|---|
| 2026-08-13 | 10-Q | 10.2 | Asset Purchase Agreement dated May 18, 2026 by and among Knight Therapeutics Europe S.A. and the Registrant (portions of the exhibit have been redacted). |
|---|
| 2026-08-13 | 10-Q | 10.1 | Sixth Amendment to Credit Agreement by and among the Company and SWK Funding LLC dated as of April 6, 2026 |
|---|
| 2026-05-14 | 10-Q | 10.1 | Asset Purchase Agreement dated February 27, 2026 by and among Pierre Fabre Medicament Sas and the Registrant (portions of the exhibit have been redacted). |
|---|
| 2026-04-15 | 8-K | 10.1 | Sixth Amendment to Credit Agreement, dated April 9, 2026, by and among Eton Pharmaceuticals, Inc. and SWK Funding LLC. |
|---|
| 2025-08-07 | 10-Q | 10.4 | Amended Offer Letter Agreement by and between the Registrant and Ipek Erdogan-Trinkaus, dated as of June 27, 2022. |
|---|
| 2025-08-07 | 10-Q | 10.3 | Amended Offer Letter Agreement by and between the Registrant and James Gruber, dated as of June 27, 2022. |
|---|
| 2025-08-07 | 10-Q | 10.2 | Amended Offer Letter Agreement by and between the Registrant and David Krempa, dated as of June 27, 2022. |
|---|
| 2025-08-07 | 10-Q | 10.1 | Amended Offer Letter Agreement by and between the Registrant and Sean Brynjelsen, dated as of June 27, 2022. |
|---|
| 2025-03-18 | 10-K | 10.14 | Licensing Agreement by and between the Company and AMMTek dated as of November 22, 2024. |
|---|
| 2025-03-18 | 10-K | 10.11 | Asset Purchase Agreement by and between the Company and Ipsen Biopharmaceuticals, Inc., dated as of October 2, 2024 (portions of the exhibit have been redacted). |
|---|
| 2025-01-03 | 8-K | 10.1 | EXHIBIT 10.1 ASSET PURCHASE AGREEMENT |
|---|
| 2024-12-12 | 8-K | 10.1 | EXHIBIT 10.1 FORM OF PURCHASE AGREEMENT |
|---|
| 2024-11-12 | 10-Q | 10.2 | Second Amendment to Warrant Agreement by and among the Company and SWK Funding LLC dated as of September 30, 2024 |
|---|
| 2024-11-12 | 10-Q | 10.1 | Fifth Amendment to Credit Agreement by and among the Company and SWK Funding LLC dated as of September 30, 2024 |
|---|
| 2023-03-16 | 10-K | 10.6 | Amended and Restated Agreement relating to sales and marketing dated February 18, 2019 between the Registrant and Eyemax, LLC (incorporated by reference to Exhibit 10.6 to the Registrant’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2019) |
|---|
| 2022-08-11 | 10-Q | 10.1 | Asset Purchase Agreement by and among the Company and Dr. Reddy’s Laboratories S.A., dated as of June 24, 2022. |
|---|
| 2022-05-12 | 10-Q | 10.1 | Credit Agreement by and among the Company, the Lenders party thereto, and SWK Funding LLC , as administrative agent dated as of November 13, 2019 and conformed through Third Amendment dated as of April 5, 2022. |
|---|
| 2021-03-16 | 10-K | 10.11 | 2018 Equity Incentive Plan (as amended December 2020 (filed herewith). |
|---|
| 2020-05-06 | 8-K | 10.1 | Promissory Note between Eton Pharmaceuticals, Inc. and Bank of America, NA |
|---|
| 2020-03-30 | 8-K | 10.3 | First Amendment to Credit Agreement dated as of March 26, 2020 by and between the Company and SWK Funding LLC, as Agent. |
|---|
| 2020-03-30 | 8-K | 10.2 | Purchase Agreement dated March 26, 2020 by and among the Company and Certain Investors |
|---|
| 2020-03-30 | 8-K | 10.1 | Securities Purchase Agreement dated March 26, 2020 by and between the Company and Opaleye L.P. |
|---|
| 2020-03-05 | 10-K | 10.14 | Exclusive License and Supply Agreement (ET-103) dated August 3, 2018 between the Registrant, Liqmeds Worldwide Limited and LM Manufacturing, Ltd. (incorporated by reference to Exhibit 10.14 to the Registrant’s Registration Statement on Form S-1, as amended (File No. 333-226774), originally filed August 10, 2018). |
|---|
| 2019-11-14 | 10-Q | 10.1 | Exclusive License and Product Development Agreement between Eton Pharmaceuticals, Inc. and Aucta Pharmaceuticals, Inc., effective as of July 30, 2019 (but executed as of June 12, 2019). (Note: Portions of this exhibit have been omitted in accordance with the SEC’s Rules on omission of confidential information) |
|---|
| 2019-05-07 | 10-Q | 10.6 | Agreement between Eton Pharmaceuticals, Inc. and Eyemax LLC, dated as of February 18, 2019 |
|---|
| 2019-05-07 | 10-Q | 10.5 | Agreement between Eton Pharmaceuticals, Inc. and Harrow Health Inc., dated as of May 6, 2019 |
|---|
| 2019-05-07 | 10-Q | 10.4 | Agreement between Eton Pharmaceuticals, Inc. and Sintetica SA, dated as of February 8, 2019 |
|---|
| 2019-05-07 | 10-Q | 10.3 | Agreement between Eton Pharmaceuticals, Inc. and Liqmeds Worldwide Limited, dated as of January 23, 2019 |
|---|
| 2019-05-07 | 10-Q | 10.2 | Agreement between Eton Pharmaceuticals, Inc. and Sintetica SA, dated as of February 8, 2019 |
|---|
| 2019-05-07 | 10-Q | 10.1 | Agreement between Eton Pharmaceuticals, Inc. and Bausch Health Ireland Limited (“BIRL”), dated as of February 18, 2019 |
|---|